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Abstract: The objective of this study was to elucidate the proteomic mechanisms of drug resistance 
in HIV-infected African patients. Cell membrane fractions from forty oral Candida isolates isolated 
from African HIV-positive patients were analysed using HPLC-MS with the aim of identifying 
proteins associated with their pathogenicity and drug resistance. Heat shock proteins that mediate the 
fungicidal activity of salivary peptides were found in all tested Candida fractions, with pH-
responsive proteins associated with increased pathogenicity only being present in the three most 
commonly isolated species. ABC multidrug transporter efflux pumps and estrogen binding proteins 
were only found in C. albicans fractions, while ergosterol biosynthesis proteins were identified in 
four species. The combination of various adherence, invasion, upregulation and efflux pump 
mechanisms appear to be instrumental for the Candida host colonization and drug resistance 
emergence in HIV-infected individuals. 
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1. Introduction 
The opportunistic yeast, Candida albicans, can cause life-threatening infections with mortality 
rates exceeding 40% in treated cases [1], paralleled by a simultaneous increase in the numbers of 
resistant non-albicans Candida species [2]. Oropharyngeal candidiasis (OC) is diagnosed clinically 
by the appearance of white, plaque-like lesions of the tongue or oropharyngeal mucosa, usually 
confirmed by laboratory culture. As an early indicator of immune suppression and HIV infection, OC 
increases the risk for AIDS-related morbidity and mortality [3] since HIV-infected individuals are 
known to have higher fungal loads than HIV-naïve patients [4]. Antifungal agents and combined 
anti-retroviral therapy (cART) are standard care at most HIV clinics. Prolonged antibiotic and 
antifungal therapy and prophylaxis are challenging in resource-limited countries, where systemic resistant 
infections are costly to treat and often result in increased patient morbidity and mortality [5]. 
Among the most commonly prescribed antifungal agents are the azoles (fluconazole, 
itraconazole, ketoconazole, voriconazole), echinocandins (anidulafungin, caspofungin, micafungin) 
and polyenes (nystatin, amphotericin B). Oral fluconazole is the treatment of choice. Patients tolerate 
fluconazole better than itraconazole and ketoconazole [6] and even though topical therapy (clotrimazole, 
nystatin and miconazole) may adequately treat initial episodes of oropharyngeal candidiasis [7], 
fluconazole is found to be more effective. 
Candida species express drug resistance and virulence-related proteins in their cell membranes, 
which are pivotal in fungal pathogenesis. Virulence is mediated through morphogenesis and invasion [8]. 
Cell membrane proteins are involved in drug modification, detoxification, and resistance in both 
prokaryotic and eukaryotic systems [9]. The following pluripotent proteins are response mechanisms 
to stress that enable survival: i) ATP-binding cassette transporters Cdr1p and Cdr2p which act as 
efflux pumps to expel azoles and other drugs in C. albicans [10,11] and elicit resistance, ii) Mdr1p, 
an efflux pump transporter implicated in C. albicans and C. dubliniensis azole resistance [12,13], iii) 
Heat shock protein Hsp90, a chaperone that binds to human salivary peptides to mediate fungicidal 
activity and is implicated in antifungal drug resistance [14,15], iv) Hsp70 proteins SSA1 and SSA2, 
which affect the fungicidal activity of human antimicrobial peptides [16]. SSA1 is associated with 
disseminated oropharyngeal disease [17], v) NADPH dehydrogenase EBP1 (estrogen binding protein 1) 
which binds with high affinity to mammalian estrogen [18], vi) pH-responsive protein 2 (PHR2), 
which may also be involved in pathogenesis [19] and vii) ECM33, an adhesin implicated in 
caspofungin resistance [20]. Additionally, lanosterol 14-alpha demethylase (Erg11p) catalyses C14-
demethylation of lanosterol, a critical step for ergosterol biosynthesis [21]. Its involvement in the 
subpathway that synthesizes zymosterol from lanosterol is affected by the action of azole drugs, 
which bind to Erg11p and reduce ergosterol production in Candida. Twenty-five other enzymatic 
reactions take place in this biosynthetic pathway, with Erg1p, Erg2p and Erg24 being used as targets 
by other antifungal drugs [22]. Upregulation of Erg11p expression has been associated with 
increased resistance to azole in C. albicans [23], C. tropicalis [24] and C. auris [25]. 
Mechanistic studies of these membrane proteins are critical to the development of novel 
therapies to combat azole resistance in Candida, particularly in immunocompromised patients. 
Therefore, the objective of this study was to elucidate the mechanisms of drug-resistance-related 
Candida proteins detected in two cohorts of African HIV-infected individuals. 
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2. Materials and methods 
2.1. Sampling 
Ethics approval was obtained from the Research Ethics Committee of the University of the 
Western Cape in Cape Town, South Africa and from the Bamenda Regional Hospital Institutional 
Review Board (IRB) in the North West Province of Cameroon under ethics protocol numbers 07/2/40 
and R.005/MPH.RDPH.RHB/359. The study protocol followed in accordance with the revised 
Declaration of Helsinki [26] and written informed consent was obtained from all participants for both 
the collection and storage of samples for future analyses. The study included HIV-positive patients 
presenting with white pseudomembranous plaque on the tongue or other visible oral candidiasis. 
Patients who received antifungals or other antimicrobial medications within two weeks prior to 
sample collection were excluded from the study. Oral swabs were collected for laboratory processing 
from 20 study participants recruited from health clinics in the Cape Flats region in Cape Town, South 
Africa and a further 20 recruited from Bamenda, Cameroon. 
2.2. Identification and antifungal drug susceptibility testing of Candida isolates 
Swab samples were plated onto Sabouraud agar (Cat. no. 84088; Sigma-Aldrich, St. Louis, MI, 
USA) and incubated at 37 ℃ for 24 hours. Presumptive species identification was achieved by 24–72 
hour culture on Fluka chromogenic Candida identification agar (Cat. no. 94382; Sigma-Aldrich, St. 
Louis, MI, USA) and Oxoid chromogenic Candida agar (Cat. no. CM1002A; Oxoid, Hampshire, 
UK), incubated at 30 ℃ and species identification was confirmed using Gram stain morphology, 
growth on selective media, the germ tube test and API ID 32 C biochemical testing (Cat. no. 32200; 
bioMérieux, Marcy l'Etoile, France). Drug susceptibility was tested against the azoles (fluconazole, 
itraconazole, posaconazole and voriconazole), echinocandins (anidulafungin, caspofungin and 
micafungin), amphotericin B and 5-flucytosine using a Clinical and Laboratory Standards Institute (CLSI) 
approved broth microdilution susceptibility platform, as previously described [27]. 
2.3. Isolation of Candida cell membrane proteins 
Drug resistance-related protein profiles expressed by different Candida species regarded as 
susceptible or resistant to azoles (as determined by CLSI guidelines) were compared, along with the 
proteins expressed using other antifungal drug classes. 
Isolates were cultured on Sabouraud agar plates for 24 hours at 37 ℃, before individual 
colonies were picked and incubated in yeast extract peptone dextrose (YPD) broth (peptone 10 g/L 
and dextrose 40 g/L distilled water) at 37 ℃ for 16 hours with agitation. Culture density was 
measured at 600 nm absorbance and the biomass was recovered by centrifugation at 3000 g. The fungal 
cell pellet was washed in 2 mL of sterile distilled water before being re-pelleted at 3000 g for 10 minutes. 
The isolated pellet was then resuspended in 2 mL homogenizing buffer with the protease inhibitor 
phenylmethylsulfonyl fluoride (PMSF) (50 mM Tris-HCl, pH 7.5, 2 mM EDTA, 1 mM PMSF), 
using a protein isolation method based on the one described by Niimi et al [10]. One-millimetre 
borosilicate glass beads (Cat. no. Z273619, Sigma-Aldrich, USA) were used to disrupt the fungal 
cells, by placing the tubes in a vortex for 6 minutes. The cell debris were pelleted at 5000 g for 10 min 
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at 4 ℃ and the lysates (containing fungal cell membrane components) were then pelleted at 20 000 g 
for 1 hour at 4 ℃, to result in a crude membrane fraction. 
Protein concentration was determined by the Bradford method [28], using a Bio-Rad Bovine 
Serum Albumin (BSA) Standards Set (Cat. no. 500-0207, Bio-Rad, USA), according to the 
manufacturer’s instructions. Sixteen microliters of a 10 mM Tris-HCl, pH 7.0, 5 mM EDTA solution 
were added to the isolated pellets, with standardized sample concentrations being subsequently 
diluted to an approximate protein concentration of 0.65 mg/mL. 
Using filter-aided sample preparation (FASP) on the cell fractions, 50 μL samples were mixed 1:1 
with SDT lysis buffer (4% SDS, 100 mM Tris-HCl pH 7.6, 0.1 M DTT), then mixed with an equal 
volume of UA buffer (8 M urea, 100 mM Tris-HCl, pH 8.5) and concentrated on an Amicon ultra 10 
kDa MWCO filter (EMD Millipore, USA) by 40 minutes centrifugation at 14000 g. For simplicity, 
all subsequent centrifugation steps were performed at 14000 g. Next, 200 μL UA buffer was added 
and the samples were again centrifuged for 40 minutes before isolated proteins were alkylated with 
the addition of 100 μL of 0.05 M iodoacetamide in UA buffer. After a 5-minute incubation and 30-
minute centrifugation, 100 μL of UB buffer (8 M urea, 0.1 M Tris-HCl pH 8.0) was added. This was 
followed by another hour centrifugation, the addition of 100 μL 50 mM ammonium bicarbonate 
solution before a 1-hour centrifugation cycle. Next, 40 μL trypsin was added and the filter was 
incubated at 37 ℃ for 17 hours in a wet chamber. The filter was subsequently transferred to a new 
tube and centrifuged for 40 minutes, followed by the addition of 40 μL of a 0.5 M sodium chloride 
solution and another 20-minute centrifugation cycle. Finally, the solution was acidified by the 
addition of 2.4 μL formic acid solution. The filtrate was then desalted using C18 StageTips (Thermo-
Fisher Scientific, USA) according to the manufacturer’s instructions, before drying in vacuo and -20 ℃ 
storage (Figure 1). Dried peptides were dissolved in 5% acetonitrile in 0.1% formic acid and 10 μL 
injections were made for nano-LC chromatography. 
2.4. HPLC-MS protein identification 
Mass spectrometry experiments were performed on a Thermo Scientific EASY-nLC II 
connected to a LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, Bremen, Germany) 
equipped with a nano-electrospray source. For liquid chromatography, separation was performed on 
an EASY-Column (2 cm, ID 100 μm, 5 μm, C18) pre-column followed by XBridge BEH130 
NanoEase (15 cm, ID 75 μm, 3.5 μm, C18) column with a flow rate of 300 nL/min. The gradient 
used was from 5–17% B in 5 min, 17–25% B in 90 min, 25–60% B in 10 min, 60–80% B in 5 min 
and kept at 80% B for 10 min. Solvent A was 100% water in 0.1% formic acid, and solvent B was 100% 
acetonitrile in 0.1% formic acid. 
The mass spectrometer was operated in data-dependent mode, to automatically switch between 
Orbitrap-MS and LTQ-MS/MS acquisition and data acquired using the Xcalibur software 
package (Thermo Scientific Cat. No. OPTON-30487). The 20 most intense ions were isolated and 
fragmented in a linear ion trap (number of accumulated ions 1.5 × 10
4
) using collision induced 
dissociation. The lock mass option (polydimethylcyclosiloxane; m/z 445.120025) enabled accurate 
mass measurement in both the MS and MS/MS modes. 
Thermo Proteome Discoverer 1.3 software (Thermo Scientific, Bremen, Germany) was used to 
identify proteins via automated database searching (Mascot, Matrix Science, London, UK, and 
Sequest) of all tandem mass spectra against the Uniprot database [29], with the aim of exclusively 
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identifying specific protein functions related to antifungal drug resistance and proteins that affected 
the organism’s pathogenicity and virulence. Proteins were considered positively identified when they 
were characterised with at least 1 tryptic peptide per protein, a Mascot score threshold of 20 and 
Sequest score threshold of 1.5. In order to include only significant data, only proteins with a mascot 
score above 24 were included in the study. 
  
Figure 1. Filter-Aided Sample Preparation (FASP) overview. Membrane protein 
denaturing and binding to the Amicon filter takes place in steps  to : The SDS 
component of the SDT buffer assists in solubilising the membrane proteins in the crude 
extract, while the DTT acts as a reducing agent, breaking disulphide residue bonds. 
Membrane proteins are further denatured with the high urea content of the UA and UB 
buffers that further destabilise internal protein bonds. Iodoacetamide is a sulfhydryl-
reactive alkylating reagent that blocks binding to the reduced cysteine residues and 
prevents disulphide bonding and protein refolding while the addition of bicarbonate 
renders the proteins in a highly-charged state, improving Amicon filter bonding. The 
addition of Trypsin and the overnight incubation at 37 ℃ in step , further denatures the 
membrane proteins that are eluted from the Amicon filter by the interaction between the 
positively-charged proteins and negatively-charged chloride ions in the sodium chloride 
solution used in step . Formic Acid further cleaves the membrane proteins into peptides 
at their C- or N- terminal domains (step ) before the eluted proteins then bind to a 
derivatised C18 filter in the StageTip (step ) through hydrophobic interactions. This 
step allows for other salts, buffers and chaotropes to be eluted. The tip with the bound 
proteins is then dried under vacuum pressure and stored at -20 ℃ until needed for HPLC-
MS. This figure was created by an author (RF) using BioRender (https://biorender.com/). 
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3. Results 
3.1. Cohort demographics and combination ART 
The majority of participants were female (80%) with a median age of 33.5 years (age range 24 
to 70). Recruits were on the following ART at the time of sample collection: 82.5% receiving 
Lamivudine, 52% on Nevirapine, 42.5% on Zidovudine, 37.5% on Stavudine, 27.5% receiving 
Efavirenz, one person (2.5%) received Tenofovir and one person received Lopinavir/ritonavir as part 
of their 1st line cART regimen. Of the 40 patients, seven (17.5%) were confirmed HIV-positive but 
planned to begin cART, pending viral load testing results. 
3.2. Drug resistance protein profiles 
Standardized cell membrane fractions from seven Candida species (C. albicans, C. dubliniensis, 
C. glabrata, C. tropicalis, C. krusei, C. rugosa and C. parapsilosis) expressing different azole 
resistance patterns, were prepared for High Performance Liquid Chromatography-Mass Spectrometry 
(HPLC-MS) analysis. 
Chromatograms obtained after HPLC-MS analysis differentiated between Candida species as 
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Figure 2. Chromatograms for (A) FCZ-susceptible C. albicans, isolate SA201; (B) FCZ-
resistant C. albicans, isolate C199; (C) FCZ-intermediate resistant C. glabrata, isolate 
SA92; (D) FCZ-resistant C. krusei, isolate C144. 
3.3. Expression of azole resistance-related proteins 
Various colonization and resistance mechanisms detected in azole-resistant isolates were 
elucidated using HPLC-MS. Representatives of heat-shock proteins were detected in all isolates. The 
identified heat shock proteins included Hsp70 (SSA1) and Hsp90 (expressed by all species). 
Hsp70 (SSA1 and SSA2) and Hsp90 were found in resistant isolates across all seven Candida 
species in our study, with Hsp70 (SSA1) expressed in seven of the nine C. glabrata strains tested. Of 
these seven, six Hsp70 (SSA1) positive isolates were also resistant to at least one azole drug tested. 
Only a single C. glabrata isolate was susceptible to all tested drug classes and did not express Hsp70, 
highlighting the possible pluripotent nature of this protein. In the C. glabrata isolate that displayed 
both fluconazole and voriconazole resistance, Hsp70 (SSA1) (UniProtKB accession number P10591) 
was expressed with the highest mascot score (1835.96) and had a high MS sequence coverage of 42.37%. 
Hsp70 (SSA1) was also identified in the membrane fractions of C. glabrata isolates that were 
susceptible to all azoles tested but were resistant to amphotericin B (one isolate) or had intermediate 
resistance to micafungin (one isolate). Heat-shock protein Hsp70 (SSA2) was expressed by resistant 
representatives of all species with the exception of C. dubliniensis. Other resistance-related 
proteins included NADPH dehydrogenase oxidoreductase EBP1 (expressed by C. albicans) and 
PHR2 (expressed by C. albicans and C. dubliniensis resistant isolates). The expression of a 
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multidrug resistance transporter protein Cdr1p was seen in two C. albicans azole-resistant fractions, 
with multidrug efflux transporter Cdr2p being present in a C. albicans isolate resistant to all four 
azole drugs tested. Transporter protein Cdr4p was also identified in eight C. albicans resistant 
fractions (Table 1). Proteins associated with ergosterol biosynthesis were found in C. albicans, C. 
dubliniensis, C. glabrata and C. tropicalis cell fractions. Although Erg11p was the most predominant 
protein in this group, other proteins that are involved in ergosterol biosynthesis were also identified. 
They included Erg9p (which synthesises squalene from farnesyl diphosphate), Erg1p (which 
synthesises squalene epoxide from squalene), Erg6p (which synthesises fecosterol from 4,4 
dimethylzymosterol) and Erg3p (which synthesises ergosta-5,7,24(28)-trienol from episterol). A C. 
albicans isolate highly resistant to all tested azole drugs had the highest detected mascot score for 
Erg11p (188.9), while also expressing Erg6p. Some proteins appeared to be more prevalent in certain 
species, for example, efflux pumps, corticosteroid and estrogen binding proteins were only present in 
C. albicans isolates, while other protein types were more widely distributed (Table 1). 
While most isolates initially selected for their susceptibility to azoles were also susceptible to 
other drug classes, one C. glabrata isolate and the sole C. rugosa representative expressed resistance 
to amphotericin B. In the latter, only salivary histatin binding heat-shock proteins Hsp70 (SSA1/2) 
and Hsp90 were identified along with PHR2. 
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Table 1. Individual drug-resistance and pathogenicity-related proteins seen in azole-susceptible and -resistant isolates, identified by HPLC-


















pH-responsive protein 2 EBP1 Hsp70 Hsp90 Erg11p Erg1p Erg3p Erg6p Erg9p 
SSA1 SSA2 












S (n = 10) √ (3) 
_ 
√ (7) √ (9) √ (4) √ (10) √ (9) √ (10) √ (3) 
_ _ 
√ (3) √ (1) 
R (n = 10) √ (2) √ (1) √ (8) √ (9) √ (3) √ (10) √ (5) √ (7) √ (5) 
_ 




S (n = 3)    √ (1) 
_ 
√ (2) √ (2) √ (2) 
_ _ _ 
√ (1) 
_ 
R (n = 6)    
_ _ 
√ (5) √ (3) √ (5) √ (3) _ √ (1) √ (1) √ (3) 
C. dubliniensis 
 
S (n = 3)    √ (2) 
_ 
√ (3) √ (2) √ (3) √ (1) √ (1) 
_ _ _ 





_ _ _ _ _ 
C. krusei 
 
S (n = 1)    
_ _ _ _ 
√ (1) 
_ _ _ _ _ 
R (n = 2)    
_ _ 
√ (1) √ (1) √ (1) 
_ _ _ _ _ 
C. tropicalis R (n = 2)    
_ _ 




C. rugosa S (n = 1)    
_ _ 
√ (1) √ (1) √ (1) 
_ _ _ _ _ 
C. parapsilosis S (n = 1)    √ (1) 
_ 
√ (1) √ (1) √ (1) 
_ _ _ _ _ 
√ : protein present; -: protein not present 
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3.4. Expression of cross-resistance-related proteins 
Isolates demonstrating cross-resistance to both azoles and other drug classes expressed PHR2, a 
protein family associated with increased pathogenicity. PHR2 was seen in multi-drug resistant C. 
dubliniensis and in three C. albicans isolates where one expressed cross-resistance to amphotericin B 
and two expressed cross-resistance to 5-flucytosine. Interestingly, one of the C. albicans azole-
resistant isolates resistant to 5-flucytosine, expressed 9 resistance-associated proteins including two 
multi-drug transporters, three distinct heat-shock proteins, NADPH dehydrogenase (EBP1), PHR2 
and two ergosterol biosynthesis proteins. Incidentally, this was the isolate expressing the highest 
mascot score for Erg11p. Another C. albicans isolate with resistance to both azoles and 5-flucytosine 
expressed a similar protein profile, with the exception of Hsp70 (SSA2) and NADPH dehydrogenase. 
3.5. Comparison of resistance protein profiles of patients on cART and those not yet on cART 
Of the patients who were not yet on cART at the time of sample collection, five were colonised 
by C. albicans (three of which were highly resistant to fluconazole and two of these also being 
resistant to 5-flucytosine), one was colonised by a multi-drug resistant (MDR) C. dubliniensis isolate 
and one was colonised by C. glabrata. When comparing the protein profiles between patients who 
were yet to start cART and those already on cART, it was noted that apart from the presence of the 
ubiquitous heat shock proteins, the species isolated from patients not on cART also expressed pH-
responsive protein 2 (seen in the MDR C. dubliniensis and four C. albicans isolates), while one of 
the Cdr1p and two Cdr4p efflux transporters were identified in two C. albicans isolates from this 
group. Ergosterol biosynthesis proteins were identified in a C. albicans isolate and in the MDR C. 
dubliniensis isolate (Erg9p, Erg11p and Erg3p) belonging to this group. 
4. Discussion 
Our previous finding of the high resistance of Candida to various antifungal drugs seen in these 
HIV patients [27] is supported by this attempt to elucidate the different mechanisms that increase the 
pathogenicity and drug resistance of these organisms. This study focused on 40 novel Candida 
isolates whose membrane protein composition were characterised to better understand their role in 
drug resistance. 
Candida species can express estrogen-and progesterone-binding proteins, explaining the higher 
predisposition of females to candidiasis [30,31] and in the current study, estrogen-binding proteins 
were identified in C. albicans cell fractions in the form of EBP1. 
The heat-shock proteins Hsp70 (SSA1 and SSA2) and Hsp90 are known to bind to 
HTN3/histatin-5 found in saliva, affecting the fungicidal activity of these native antimicrobial 
proteins [14,15,32] and leading to resistance [33] and increased oral Candida colonization [34], 
especially in immunocompromised patients [35]. Histatins are small (7–38 amino acids) histidine-
rich, broad spectrum, cationic immunological peptides that act on the cell membrane causing pore 
formation and fungal cell lysis. Demonstrating potent antifungal activity, histatins are known to 
interact with Hsp70 (SSA1/2) and kill Candida [32]. Hsp70 (SSA1) was previously reported to be 
upregulated in fluconazole-resistant membrane fractions of C. glabrata [36], while in contrast, it was 
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found by the same group to be downregulated in voriconazole-resistant isolates [37]. The presence of 
Hsp70 (SSA1) in most tested isolates, the ability of this protein to affect the fungicidal activity of the 
host’s antimicrobial peptides [16] and its association with oropharyngeal disease [17] are factors that 
can directly influence the treatment outcomes of HIV patients.The ubiquitous Hsp90, on the other 
hand, has a role in supporting cell survival by stabilizing enzymes during stress [13], but has also 
been implicated in the rapid acquisition [38] and increased fluconazole resistance in Candida 
biofilms [15]. 
Multidrug resistance proteins were detected in most C. albicans cell membrane fractions tested 
in this study. The appearance of multidrug resistance protein Cdr1p may lead to resistance to a range 
of compounds as well as to azole antifungal drugs [39]. Cdr1p plays a role in fluconazole drug 
resistance [40] and confers resistance to cycloheximide, chloramphenicol and miconazole [41]. The 
up-regulation of Cdr1p in the cell membrane of a C. glabrata fluconazole-resistant strain [42] and in 
azole-resistant C. parapsilosis [43] have previously been documented, but this protein was not 
detected in membrane fractions of azole resistant C. glabrata in the present study. The sole C. 
parapsilosis isolate tested in this study was a highly susceptible isolate, possibly explaining the lack 
of this drug resistance mechanism on this strain. Cdr2p (identified in a C. albicans isolate resistant to 
all four azole drugs tested) has the ability to not only confer resistance to azoles but also to other 
antifungals such as terbinafine and amorolfine in addition to metabolic inhibitors [44]. The ability of 
histatin-5 to inhibit the development of Cdr1p and Cdr2p-mediated multidrug resistance [45], 
demonstrates how various cellular mechanisms may act together to modulate fungal pathogenicity. 
The identification of Cdr4p in eight drug-resistant C. albicans cell membrane fractions deserves attention 
since Cdr4p is an ABC transporter protein involved in azole resistance in filamentous fungi [46]. 
Five of the 25 proteins involved in ergosterol biosynthesis were found in this study. Azole drugs 
target this biosynthesis pathway by inhibiting Erg11p, leading to a block in ergosterol synthesis and 
the accumulation of toxic sterol intermediates by Erg6p and Erg3p [22]. Candida is known to mutate 
the Erg11 gene [23,47] and demonstrate drug target overexpression of Erg11p [48] as part of its 
resistance mechanisms against azole drugs. 
Coupled with filter-aided sample preparation, HPLC is a useful method for demonstrating 
antifungal susceptibility profiles and, with further developments in sample preparation, could 
become a rapid, reliable and practical technique for the early detection of resistance and subsequent 
prompt treatment of resistant Candida infections. HPLC analysis can be completed within hours, 
favouring its application over the traditional time-consuming processes of culture and disc diffusion 
or microdilution methods for drug susceptibility testing which may take days to complete. 
Comparatively, the cost, equipment specifications and skilled operators needed to perform FASP-
HPLC analysis outweigh those associated with traditional drug resistance testing methods, not to 
mention the higher fungal biomass needs in relation to more sensitive molecular sequencing methods. 
Although the introduction of cART has vastly improved the quality of life for the HIV-infected, 
it has minimally impacted the observed number of Candida infections [49,50]. The large number of 
immunocompromised HIV-positive patients in Africa receiving non-protease-inhibitor-based first 
line cART [51] and the prevalence of multidrug-resistant candidiasis, suggests a bleak future, barring 
any natural therapeutic intervention without adverse cART interactions [52]. A limitation of this 
study is that since only seven of the 40 isolates were collected before the commencement of cART, 
an association between the effect of cART on protein expression could not adequately be compared, 
thus creating an avenue which may be further explored. 
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Furthermore, the inability to significantly differentiate between individual protein expression 
profiles and their relation to specific antifungal classes in MDR isolates indicates that further 
optimization of the protein isolation methods should be prioritized in future studies. In spite of this 
methodological limitation, it was possible to identify the presence of protein profiles in organisms 
expressing specific drug resistance patterns within the different species studied. The combination of 
diverse drug resistance and survival mechanisms were notably more prevalent in C. albicans, C. 
dubliniensis and the inherently fluconazole-resistant C. glabrata. These isolates expressed proteins 
that enhance their fungicidal activity by increasing their adherence to salivary peptides and 
improving the binding of fungal proteins to mammalian hormones, modifications that are 
instrumental in the ability of these organisms to colonise immunocompromised patients and resist 
antifungal drugs. 
The possibility exists that cell membrane changes could have occurred in response to 
environmental stress, such as pH changes during protein isolation, rather than to stress induced by 
drugs. Additionally, given that most UniProt strains are isolates from other geographical regions, and 
since there is a paucity of studies on isolates from Africa, it is possible that the isolates have 
sequence polymorphisms and different amino acid sequences when compared to other previously 
tested populations. In essence, the limited MS data for Candida isolates from sub-Saharan Africa 
identifies the lack of proteomics-based drug resistance monitoring in this study’s sample populations. 
5. Conclusions 
Fluconazole-resistance is steeply rising, and it is the most frequently prescribed antifungal for 
HIV-associated opportunistic infections. Antifungals such as echinocandins, are usually considered 
for treating patients who show resistance due to previous azole exposure, or when C. glabrata, C. 
parapsilosis or C. krusei have been identified [53]. Although shown to be as effective in treating OC 
with less serious side effects, echinocandins have a greater relapse rate, contributing significantly to 
ever-increasing antifungal resistance prevalence [54,55]. Amphotericin B is used when patients show 
resistance to fluconazole and echinocandins. However, in very ill patients, it may prove toxic [56] 
and has limited availability in resource-poor countries due to its cost. 
Reported drug interactions between systemic antifungals (particularly azoles) and antiretrovirals 
have led to the addition of special guidelines for their use with combination ART for HIV-infected 
persons by the US Department of Health and Human Services [57]. Moreover, the evolving drug 
resistance and subsequent circulation of multidrug-resistant or inherently drug-resistant, non-albicans 
species in the treatment-naïve population not only limits treatment options but may also reduce the 
tolerance of combination ART through drug interactions. 
Thus, there is an urgent need for the development of novel, non-toxic, broad spectrum, highly 
potent, natural antifungal therapies. HPLC provides beneficial protein abundance data that is 
essential for understanding the role of individual proteins in drug resistance mechanisms in vitro, 
thus establishing a role in studies contributing to the development of novel therapies. 
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